[1] YANG Z, ZHENG R, ZHANG S, et al. Incidence, distribution of histological subtypes and primary sites of soft tissue sarcoma in China[J]. Cancer Biol Med, 2019, 16(3): 565-574.
[2] 叶挺, 张洁莹, 周瑀涵, 等. 软组织肉瘤化疗研究进展[J]. 骨科临床与研究杂志, 2021, 6(2): 120-124.
[3] FUCHS J W, SCHULTE B C, FUCHS J R, et al. Targeted therapies for the treatment of soft tissue sarcoma[J]. Front Oncol, 2023, 13: 1122508.
[4] APTE R S, CHEN D S, FERRARA N. VEGF in signaling and disease: beyond discovery and development[J]. Cell, 2019, 176(6): 1248-1264.
[5] LI J, QIN S, XU J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial[J]. J Clin Oncol, 2013, 31(26): 3219-3225.
[6] FERRARA N, GERBER H P, LECOUTER J. The biology of VEGF and its receptors[J]. Nat Med, 2003, 9(6): 669-676.
[7] HU X, CAO J, HU W, et al. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer[J]. BMC Cancer, 2014, 14: 820.
[8] QIU H, LI J, LIU Q, et al. Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel[J]. Cell Cycle, 2018, 17(10): 1235-1244.
[9] WANG C, JIANG M, HOU H, et al. Apatinib suppresses cell growth and metastasis and promotes antitumor activity of temozolomide in glioma[J]. Oncol Lett, 2018, 16(5): 5607-5614.
[10] LIU K, REN T, HUANG Y, et al. Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma[J]. Cell Death Dis, 2017, 8(8): e3015.
[11] JIN Z, CHENG X, FENG H, et al. Apatinib inhibits angiogenesis via suppressing Akt/GSK3β/ANG signaling pathway in anaplastic thyroid cancer[J]. Cell Physiol Biochem, 2017, 44(4): 1471-1484.
[12] 左立杰, 刘维丽, 李蕊, 等. 阿帕替尼治疗晚期软组织肉瘤的临床疗效和安全性[J]. 癌症进展, 2019, 17(4): 427-430, 448.
[13] 付浩然, 赵雪峰, 李勇, 等. 阿帕替尼治疗腹腔低度恶性肌纤维母细胞肉瘤1例及文献回顾[J]. 癌症进展, 2023, 21(17): 1970-1972.
[14] 龚涛军, 何梅, 王一天, 等. 阿帕替尼治疗软组织肉瘤的有效性及安全性27例回顾分析[J]. 中国骨与关节杂志, 2020, 9(5): 341-347.
[15] FUCHS C S, TOMASEK J, YONG C J, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial[J]. Lancet, 2014, 383(9911): 31-39.
[16] SHAO F, ZHANG H, YANG X, et al. Adverse events and management of apatinib in patients with advanced or metastatic cancers: a review[J]. Neoplasma, 2020, 67(4): 715-723. |
